Abstract

 
BACKGROUND:
Severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which was declared as a global pandemic by the World Health Organization (WHO) on 11th March 2020. SARSCoV-2 was discovered in Wuhan City, China, in December 2019. The first patient with COVID-19 was reported in Iraq on 24 February 2020. At 15 July 2022 the Iraqi Ministry of Health reported 2,334,375 confirmed cases, a number of which 25,229  patients died, and 10,813,380 vaccinations were administered.
OBJECTIVE:
To find out how well a treatment plan works and what associated factors are involved among a group of COVID-19 patients. 
PATIENTS AND METHODS:
A cross-sectional study in which a review of patients records   was carried out at two designated centers for COVID 19 patients; Dar Al Salam hospital in Baghdad- Al Karkh side and Al Shefaa center in Al Kindy hospital, Baghdad- Al Rusafa side from first of August 2021 to 31 January 2022.
RESULTS:
A total of 304 COVID 19 patients were included in this study. There were 219 (72%) recovered patients and 85 (28%) deaths. Respiratory failure was the most common cause of death among patients 48 (15.8%), Followed by Renal failure then 27 (8.9%), and sepsis & septic shock 10 (3.3%). Recovery rate appeared to be significantly higher among patients without gastrointestinal tract (GIT) symptoms, with acceptable oxygen saturation, and of moderate severity, P=0.001, P<0.001, and P<0.001 respectively.
CONCLUSION:
Comorbidities including diabetes mellitus, hypertension, hypothyroidism, asthma, cerebrovascular diseases, Rheumatic disease, and obesity were without a  statically significant association with\ the recovery but high  mortality rate. Patients who were taking steroids  were significantly more\ in recovered group.